Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 28,081 $ 48,995
Marketable securities 213,126 129,669
Accrued interest receivable 725 304
Prepaid expenses 7,881 2,594
Total current assets 249,813 181,562
Property and equipment, net 2,693 2,905
Operating lease right-of-use asset 199  
Other assets 730 2,280
Total assets 253,435 186,747
Current liabilities:    
Accounts payable 2,882 1,973
Accrued clinical trial expenses 9,274 8,588
Other accrued liabilities 3,266 3,854
Total current liabilities 15,422 14,415
Long-term portion of operating lease liability 1,954  
Other liabilities   1,914
Total liabilities 17,376 16,329
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 100,000,000 shares authorized; 68,701,043 and 59,456,493 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively 7 6
Additional paid-in capital 806,001 693,534
Accumulated other comprehensive income (loss) 228 (58)
Accumulated deficit (570,177) (523,064)
Total stockholders’ equity 236,059 170,418
Total liabilities and stockholders’ equity $ 253,435 $ 186,747